These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 30662577)

  • 21. mTORC1 and mTORC2 are differentially engaged in the development of laser-induced CNV.
    Yang JY; Madrakhimov SB; Ahn DH; Chang HS; Jung SJ; Nah SK; Park HY; Park TK
    Cell Commun Signal; 2019 Jun; 17(1):64. PubMed ID: 31200728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The anti-osteosarcoma cell activity by a mTORC1/2 dual inhibitor RES-529.
    Hu X; Wang Z; Chen M; Chen X; Liang W
    Biochem Biophys Res Commun; 2018 Mar; 497(2):499-505. PubMed ID: 29432734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
    Wicki A; Brown N; Xyrafas A; Bize V; Hawle H; Berardi S; Cmiljanović N; Cmiljanović V; Stumm M; Dimitrijević S; Herrmann R; Prêtre V; Ritschard R; Tzankov A; Hess V; Childs A; Hierro C; Rodon J; Hess D; Joerger M; von Moos R; Sessa C; Kristeleit R
    Eur J Cancer; 2018 Jun; 96():6-16. PubMed ID: 29660598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PP242 Counteracts Glioblastoma Cell Proliferation, Migration, Invasiveness and Stemness Properties by Inhibiting mTORC2/AKT.
    Mecca C; Giambanco I; Bruscoli S; Bereshchenko O; Fioretti B; Riccardi C; Donato R; Arcuri C
    Front Cell Neurosci; 2018; 12():99. PubMed ID: 29692710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of mTORC1 and mTORC2 in Breast Cancer: Therapeutic Targeting of mTOR and Its Partners to Overcome Metastasis and Drug Resistance.
    Butt G; Shahwar D; Qureshi MZ; Attar R; Akram M; Birinci Y; Karatoprak GS; Gasparri ML; Farooqi AA
    Adv Exp Med Biol; 2019; 1152():283-292. PubMed ID: 31456190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The phosphoinositide 3-kinase signaling pathway as a therapeutic target in grade IV brain tumors.
    Höland K; Salm F; Arcaro A
    Curr Cancer Drug Targets; 2011 Oct; 11(8):894-918. PubMed ID: 21861842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphoproteomic Analysis Defines BABAM1 as mTORC2 Downstream Effector Promoting DNA Damage Response in Glioblastoma Cells.
    Kalpongnukul N; Bootsri R; Wongkongkathep P; Kaewsapsak P; Ariyachet C; Pisitkun T; Chantaravisoot N
    J Proteome Res; 2022 Dec; 21(12):2893-2904. PubMed ID: 36315652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC).
    Zhang Y; Jia QA; Kadel D; Zhang XF; Zhang QB
    Med Sci Monit; 2018 May; 24():2735-2743. PubMed ID: 29720580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TIS21
    Sundaramoorthy S; Devanand P; Ryu MS; Song KY; Noh DY; Lim IK
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1445-1462. PubMed ID: 29808317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities.
    Oh S; Yeom J; Cho HJ; Kim JH; Yoon SJ; Kim H; Sa JK; Ju S; Lee H; Oh MJ; Lee W; Kwon Y; Li H; Choi S; Han JH; Chang JH; Choi E; Kim J; Her NG; Kim SH; Kang SG; Paek E; Nam DH; Lee C; Kim HS
    Nat Commun; 2020 Jul; 11(1):3288. PubMed ID: 32620753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Twenty-five years of mTOR: Uncovering the link from nutrients to growth.
    Sabatini DM
    Proc Natl Acad Sci U S A; 2017 Nov; 114(45):11818-11825. PubMed ID: 29078414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment.
    Tanaka K; Sasayama T; Irino Y; Takata K; Nagashima H; Satoh N; Kyotani K; Mizowaki T; Imahori T; Ejima Y; Masui K; Gini B; Yang H; Hosoda K; Sasaki R; Mischel PS; Kohmura E
    J Clin Invest; 2015 Apr; 125(4):1591-602. PubMed ID: 25798620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy.
    Sathe A; Chalaud G; Oppolzer I; Wong KY; von Busch M; Schmid SC; Tong Z; Retz M; Gschwend JE; Schulz WA; Nawroth R
    PLoS One; 2018; 13(1):e0190854. PubMed ID: 29357370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting mTOR in Acute Lymphoblastic Leukemia.
    Simioni C; Martelli AM; Zauli G; Melloni E; Neri LM
    Cells; 2019 Feb; 8(2):. PubMed ID: 30795552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
    Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
    Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced menin expression impairs rapamycin effects as evidenced by an increase in mTORC2 signaling and cell migration.
    Razmara M; Monazzam A; Skogseid B
    Cell Commun Signal; 2018 Oct; 16(1):64. PubMed ID: 30285764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanistic target of rapamycin complex 1 and 2 in human temporal lobe epilepsy.
    Talos DM; Jacobs LM; Gourmaud S; Coto CA; Sun H; Lim KC; Lucas TH; Davis KA; Martinez-Lage M; Jensen FE
    Ann Neurol; 2018 Feb; 83(2):311-327. PubMed ID: 29331082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.